Clinical experience
Integrated by clinicians and pharmacists specialized in the field of clinical pharmacology and physicians specialized in internal medicine, cardiology, neurology, clinical geneticists, biologists and bioinformaticians
Knowledge Management
Expert detailed curation of Scientific Literature and recommendations of the main clinical pharmacogenetics guidelines
Sequencing panel design
Deep sequencing NGS approach with an in-house designed panel. Allows for the study of highly polymorphic genes and structural variants (CNVs)
Pharmacogenetics Global Panel
[85 DRUGS, 17 GENES AND 935 GENETICS REGIONS]
The pharmacogenetics global panel analyzes genetic-based variation in response to different drugs within a single panel. The study includes all drugs and genetic variants included in the recommendations of the main clinical pharmacogenetics guidelines.
The global pharmaHIC panel provides information on treatment individualization for 85 drugs, 17 genes, and 935 genetic regions.
TAT [turnaround time]: 5 weeks
STUDIED DRUGS:
Central Nervous System
Antidepressants
Selective serotonin reuptake inhibitors
(SSRIs): citalopram, escitalopram, fluvoxamine, paroxetine, sertraline.
Selective serotonin and noradrenalin reuptake inhibitor (SNRIs): venlafaxine, desvenlafaxine, duloxetine.
Tricyclic antidepressants (TCA): amitriptyline, clomipramine, doxepin, imipramine, nortriptyline, trimipramine.
Other antidepressants: mirtazapine, moclobemide, vortioxetine, nefazodone.
Antipsychotics
First generation antipsychotics (FGA): haloperidol, zuclopenthixol, pimozide, perphenazine.
Second generation antipsychotics (SGA): aripiprazole, clozapine, olanzapine, risperidone.
Antiepileptics: phenytoine, carbamazepine, oxcarbazepine.
Centrally acting sympathomimetics: atomoxetine.
Benzodiazepines: diazepam, clobazam, brivaracetam.
Digestive System
Antiemetic 5-HT3 antagonists: ondansetron, tropisetron.
Gastric protectors (Proton pump inhibitors): esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole.
Analgesics
Codeine, tramadol, oxyodone.
Antineoplastic and immunosuppressive agents
Fluoropyrimidines: 5-fluorouracil, capecitabine.
Topoisomerase inhibitors: irinotecan.
Hormone therapy: tamoxifen.
Thiopurines: azathioprine, mercaptopurine, thioguanine.
Calcineurin inhibitors: tacrolimus.
Anthracyclines: doxorubicin, daunorubicin.
Platins: cisplatin.
Cardiovascular system
Antiplatelet agents: clopidogrel, ticagrelor.
Oral anticoagulants: acenocoumarol, warfarin, apixaban, rivaroxaban.
Hypolipidemic agents: atorvastatin, fluvastatin, lovastatin, pitavastatin, simvastatin, rosuvastatin, pravastatin.
Beta blockers: bisoprolol, carvedilol, metoprolol, nebivolol, propranolol.
Antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone.
Infectious diseases
Antifungal agents: voriconazole.
Antiviral agents-HCV: peginterferon alfa-2A, peginterferon alfa-2B, ribavirin.
Antiretroviral agents-HIV: abacavir, atazanavir.
Endocrine system and metabolism
Oral antidiabetics
Sulfonylureas: gliclazide, glimepiride, glibenclamide, tolbutamide.
Hypouricemic agents: allopurinol, rasburicase.
Contraceptives:: estrogen oral contraceptives.
| CYP1A2 (16 alleles, 14 regions) | CYP2C9 (13 alleles, 14 regions) | CYP3A4 (22 alleles, 20 regions) |
| F5 (1 allele, 1 region) | HLA-A (1 allele, 1 region) | IFNL3 (1 allele, 1 region) |
| SLC28A3 (1 allele, 1 region) | TPMT (12 alleles, 7 regions) | UGT1A6 (6 alleles, 4 regions) |
| CYP2C19 (15 alleles, 15 regions) | CYP2D6 (28 alleles, 24 regions, CNVs studies) | DPYD (12 alleles, 10 regions) |
| G6PD (212 alleles, 173 regions) | HLA-B (2932 alleles, 627 regions) | RARG (1 allele, 1 regions) |
| SLCO1B1 (19 alleles, 15 regions) | UGT1A1 (8 alleles, 6 regions) | VKORC1 (1 allele, 1 region) |
Health in Code’s Genetic Studies:
